Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.51 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030449 | 0.83 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL10537812 | 0.79 | MAPT (0.62) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL10537818 | 0.79 | MAPT (0.62) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL2033623 | 0.78 | MAPT (0.54) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL27741821 | 0.75 | MAPT (0.60) | MAPTSMN1; SMN2MAPK1CYP1B1CXCL12 | |
| SCHEMBL1678003 | 0.73 | TSHR (0.60) | MAPTSMN1; SMN2CXCL12LMNAHTT | |
| SCHEMBL10384632 | 0.71 | MAPT (0.65) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL981600 | 0.71 | MAPT (1.00) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL12948682 | 0.71 | MAPT (1.00) | MAPTRAB9ASMN1; SMN2MAPK1CYP1A1 | |
| SCHEMBL2030450 | 0.71 | CYP2D6 (0.70) | MAPTRAB9ASMN1; SMN2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192589-B2 | Chalcones as enhancer of antimicrobial agents | COLGATE-PALMOLIVE COMPANY (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2512461-B1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | COLGATE PALMOLIVE CO (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2512461-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | Colgate-Palmolive Company (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120251464-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | INDIAN INSTITUTE OF INTEGRATIVE MEDICINE (IN) | 2012-10-04 | — | — | US | disclosed |
| WO-2011075136-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | COLGATE-PALMOLIVE COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251464-A1 | CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS | LSS, CYP51A1, ELANE | MAPT 3666/4885RAB9A 3941/4885SMN1; SMN2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.